Since that time, additional ALK fusion partners have been identified and transforming versions of ALK as well as aberrant ALK expression have been shown in cancers other than lymphoma including adenocarcinomas of the lung [31], [32], neuroblastomas [33]–[37], breast [38] and esophageal cancers [39], [40]. The gene discussed is ALK; the disease is esophageal cancer.